4:48 PM
 | 
Dec 27, 2012
 |  BC Extra  |  Clinical News

Voclosporin misses endpoint in uveitis Phase III

Isotechnika Pharma Inc. (TSX:ISA) said Luveniq voclosporin missed the primary endpoint in a Phase III trial to treat non-infectious uveitis. Partner Lux Biosciences Inc. (Jersey City,...

Read the full 122 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >